Welcome to our dedicated page for Inogen news (Ticker: INGN), a resource for investors and traders seeking the latest updates and insights on Inogen stock.
Inogen Inc. (INGN) is a pioneering medical technology company committed to enhancing the quality of life for supplemental oxygen users. Founded in 2001, Inogen emerged from a personal story of necessity and innovation. The company's mission began when Mae, the grandmother of one of the founders, was prescribed oxygen therapy, highlighting the need for more user-friendly and portable oxygen solutions. You can learn more about Mae's story here.
Inogen aims to revolutionize oxygen therapy technology, striving to keep pace with the active lifestyles of patients who rely on oxygen to lead fulfilling lives. The company estimates that over 2.5 million patients in the United States and more than 4.5 million patients worldwide use oxygen therapy.
The company's flagship product, the Inogen One system, is a compact, lightweight, and travel-approved portable oxygen concentrator designed to liberate patients from the constraints of heavy tanks, frequent refills, and stationary systems. This innovation provides patients with the freedom and independence to live their lives by moments, not by the minutes left in an oxygen tank.
Inogen's products and services are sold through various channels, including home medical equipment providers, distributors, large gas companies, and home oxygen providers. The company also rents its products directly to patients, generating the majority of its revenue within the United States.
Inogen's commitment to continuous improvement is evident in its ongoing projects and recent achievements. The company constantly works toward refining its product offerings and expanding its reach to benefit more patients globally.
Inogen, Inc. (NASDAQ: INGN), a medical technology company, announced its participation in the KeyBanc Life Sciences & MedTech Investor Forum. The presentation is scheduled for March 23, 2021, at 3:30 p.m. ET, featuring President and CEO Nabil Shabshab, and CFO Alison Bauerlein. Interested individuals can access the webcast on Inogen's Investor Relations page. The company emphasizes transparency by utilizing its website to disclose non-public material information in compliance with Regulation FD. Inogen develops innovative portable oxygen concentrators for patients with chronic respiratory conditions.
Inogen, a medical technology company, reported Q4 2020 revenue of $74 million, down 6.3% year-over-year, primarily impacted by COVID-19. Domestic B2B sales rose 17.9% to $24.2 million, while rental revenue surged 71.7% to $9.4 million. The company incurred a net loss of $5.1 million and had cash reserves of $231.2 million with no debt. For 2021, Inogen refrained from providing financial guidance due to market uncertainties but anticipates improvements in domestic sales and rental revenue despite expected declines in international and direct-to-consumer sales.
Inogen, Inc. (NASDAQ: INGN) announced the appointment of Kristen Miranda to its Board of Directors, effective March 1, 2021, filling the vacancy left by Scott Beardsley’s resignation. Miranda brings extensive healthcare experience, having served as Aetna’s West Region President since 2017. Her addition aims to enhance payor acceptance of Inogen’s products. CEO Nabil Shabshab emphasized her healthcare background as a key asset for expanding patient access and enhancing shareholder value. The company continues to focus on innovative respiratory solutions for homecare settings.
Inogen, Inc. (NASDAQ: INGN) announced its participation in the 10th Annual SVB Leerink Healthcare Conference, scheduled for February 25, 2021. CEO Nabil Shabshab and CFO Alison Bauerlein will present at 2:20 p.m. ET. The presentation can be accessed via the Investor Relations page on Inogen's website, with a replay available for 90 days post-event. Inogen focuses on developing innovative respiratory products, particularly portable oxygen concentrators for patients with chronic respiratory conditions.
Inogen, Inc. (Nasdaq: INGN) will release its fourth quarter and year-end 2020 financial results on February 24, 2021, after market close. Following the release, a conference call will be held at 1:30 PM PT/4:30 PM ET, where investors can participate by calling (877) 841-3961 domestically or (201) 689-8589 internationally. A replay will be available from February 24, 2021, at 3:30 PM PT until March 10, 2021. Inogen specializes in respiratory products, particularly portable oxygen concentrators for patients with chronic respiratory conditions.
Inogen, Inc. (NASDAQ: INGN) has appointed Nabil Shabshab as President and CEO, effective February 8, 2021, succeeding Scott Wilkinson, who is retiring. Shabshab brings extensive experience from Becton Dickinson, where he served as Worldwide President of Diabetes Care. The Board expressed confidence in Shabshab's leadership to drive growth and enhance patient access to innovative respiratory products. Inogen is recognized for its portable oxygen concentrators aimed at improving the lives of respiratory therapy patients.
Inogen, Inc. (NASDAQ: INGN) has announced its participation in the 39th Annual J.P. Morgan Healthcare Conference. The Company’s President and CEO, Scott Wilkinson, along with CFO, Alison Bauerlein, will present on January 12, 2021, at 5:20 p.m. EST. Investors can access a live audio webcast through Inogen's Investor Relations page, with a replay available for 90 days post-event. Inogen specializes in developing and marketing portable oxygen concentrators for patients with chronic respiratory conditions, emphasizing its commitment to innovation in homecare respiratory products.
Inogen (NASDAQ: INGN) announced participation in the Stifel 2020 Virtual Healthcare Conference, where President and CEO Scott Wilkinson, along with CFO Alison Bauerlein, will present on November 17, 2020, at 4:00 p.m. EST. Interested parties can access the live audio webcast via Inogen's Investor Relations page. A replay will be available after the live event for 90 days. Inogen specializes in innovative respiratory products, primarily portable oxygen concentrators for patients with chronic respiratory conditions.
Inogen, Inc. (NASDAQ: INGN) reported Q3 2020 financial results, showing total revenue of $74.3 million, a 19.0% decline year-over-year, primarily attributed to the COVID-19 pandemic. Sequentially, revenue grew by 3.7%. Rental revenue increased by 40.1% to $7.5 million. The company faced a net loss of $1.7 million and an operating loss of $2.0 million. As of September 30, 2020, cash and equivalents stood at $220.5 million with no debt. The company anticipates ongoing adverse impacts from COVID-19 into Q4 2020, with revenue expected to decline compared to Q3.
Inogen, a medical technology company specializing in respiratory products, will announce its third quarter 2020 financial results on November 4, 2020, after market close. The company will host a conference call at 1:30 PM PT/4:30 PM ET for investors and analysts to discuss the results. Interested participants can join by calling the provided numbers or by accessing the live webcast through Inogen's Investor Relations website. A replay of the call will be available until November 18, 2020. For more information, visit the Inogen website.
FAQ
What is the current stock price of Inogen (INGN)?
What is the market cap of Inogen (INGN)?
What does Inogen Inc. do?
What is Inogen's flagship product?
How does Inogen sell its products?
Where does Inogen generate most of its revenue?
How many patients use oxygen therapy according to Inogen?
What makes Inogen's products stand out?
What is the mission of Inogen Inc.?
Who inspired the founding of Inogen?
Where can I learn more about Inogen's history?
What is Inogen Inc.'s stock symbol?
